Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 4 Stomach Neoplasms 3 Triple Negative Breast Neoplasms 2 Advanced Solid Tumor 2 Advanced Cancer 2 Solid Tumor, Adult 1 Recurrence 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 NSCLC 1 Mouth Neoplasms 1 Extensive Stage Small Cell Lung Cancer 1 Esophageal Squamous Cell Carcinoma 1 Cytochrome P450 Interaction 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Biliary Tract Malignancies 1 Adenocarcinoma of Lung 1 Adenocarcinoma 1

Interventions

aflutinib 3 osimertinib 2 Radiotherapy 2 tipifarnib 1 apatinib 1 Radiosurgery 1 Immune Checkpoint Inhibitors 1 Gefitinib 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × NSCLC × apatinib × Clear all

NCT04390984 2021-01-11

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡